Screener
Xenon Pharmaceuticals XENE Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Other liabilities, long-term | 3,287 | 3,199 |
| Total liabilities | $53,376 | $51,403 |
| Shareholders’ equity: | ||
| Common shares, without par value; unlimited shares authorized; issued and outstanding: 96,752,884 (December 31, 2025 - 80,010,790) (note 8) | $2,426,619 | $1,598,571 |
| Additional paid-in capital | 276,851 | 228,234 |
| Accumulated deficit | (1,458,418) | (1,245,380) |
| Accumulated other comprehensive income (loss) | (2,656) | 335 |
| Total shareholders’ equity | $1,242,396 | $581,760 |
Item 1. Financial Statements
FAQ
- What is Xenon Pharmaceuticals's common stock?
- Xenon Pharmaceuticals (XENE) reported common stock of $2.43B in Q2 2026.
- How has Xenon Pharmaceuticals's common stock changed year-over-year?
- Xenon Pharmaceuticals's common stock increased by 65.2% year-over-year, from $1.47B to $2.43B.
- What is the long-term trend for Xenon Pharmaceuticals's common stock?
- Over 5 years (2020 to 2025), Xenon Pharmaceuticals's common stock has grown at a 32.1% compound annual growth rate (CAGR), from $397.75M to $1.6B.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Xenon Pharmaceuticals's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude